Physician profile
April Michele Baisden
NPI 1376763144
$774,912.37
in general payments reported to CMS, 2019-2025
21 companies · $153K in 2025
The $153K reported for 2025 was more than what 99% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $61K · 2020: $61K · 2021: $76K · 2022: $132K · 2023: $135K · 2024: $157K · 2025: $153K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $410K · Travel and Lodging: $27K · Food and Beverage: $7,150 · Education: $14.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $410,107.50 |
| Travel and Lodging | $27,227.91 |
| Food and Beverage | $7,150.27 |
| Education | $14.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $602,012.98 | 2021-2025 | Vraylar, Ubrelvy |
| Allergan, INC. | $122,031.06 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $49,509.13 | 2024-2025 | Fanapt |
| Alkermes, INC. | $262.41 | 2019-2025 | Lybalvi, Aristada, Vivitrol |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $194.20 | 2023-2025 | Caplyta |
| Axsome Therapeutics, INC. | $164.58 | 2022-2025 | Auvelity |
| Neurocrine Biosciences, INC. | $93.41 | 2024-2025 | Ingrezza |
| Novo Nordisk INC | $83.99 | 2021-2023 | Rybelsus, Ozempic |
| Otsuka America Pharmaceutical, INC. | $80.54 | 2022-2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $77.94 | 2022-2023 | Austedo, Austedo Xr |
| Lundbeck LLC | $66.42 | 2024-2025 | Rexulti |
| Indivior INC. | $58.60 | 2024-2025 | Sublocade |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $56.79 | 2022-2023 | Xifaxan |
| E.R. Squibb & Sons, L.L.C. | $44.91 | 2025 | Cobenfy |
| Astellas Pharma US INC | $40.74 | 2025 | Veozah |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $40.32 | 2023 | Cologuard Collection Kit |
| Sunovion Pharmaceuticals INC. | $23.50 | 2019 | |
| Xeris Pharmaceuticals, INC. | $20.51 | 2023 | Keveyis |
| Ironshore Pharmaceuticals INC. | $18.70 | 2022 | |
| Lilly USA, LLC | $17.98 | 2022 | |
| Janssen Pharmaceuticals, INC | $13.66 | 2025 | Spravato |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw April Baisden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.